Through the synergistic action of multiple signaling pathways, SGLT-2 inhibitors comprehensively improve renal metabolic status, reduce oxidative stress and inflammation, and inhibit fibrosis, thereby effectively delaying the progression of non-diabetic CKD (47). This evidence concerns the gene SLC5A2 and chronic kidney disease.